The AI Divide: One-Third of Venture Capital Went Beyond Artificial Intelligence in June 2026

Five hundred sixty-six startups in artificial intelligence raised capital last month. One hundred seventy-five others did not.

The ratio tells the real story of venture capital in June 2026: AI has captured more than two-thirds of all funding announcements, a phenomenon so dominant that it obscures an equally important truth—one-third of all venture activity happens in sectors where machine learning plays no central role. That represents hundreds of millions of dollars flowing into biotech, climate energy, space technology, fintech, and dozens of niche verticals that rarely make headline aggregators.

The venture market hasn't bifurcated into "AI" and "everything else"—but it's close. And that gap is worth understanding, because the outcome matters for investors, founders, and the shape of innovation for the decade ahead.

The Numbers Behind the Narrative

Across the 30-day window from mid-June to mid-July 2026, InforCapital tracked 849 venture capital funding announcements. Of these:

• 566 deals (66.7%) involved AI or machine learning in the company's core offering
• 283 deals (33.3%) were in other sectors entirely

On the surface, this looks like AI has won. But that interpretation misses the density and diversity of non-AI funding. The 283 non-AI deals span more than thirty distinct sectors, from cleantech to quantum computing to dental management software. The scatter suggests that capital, while concentrated in AI, remains distributed across the full spectrum of startup creation.

What makes the one-third figure striking is its constancy. Month after month, venture capital allocates roughly 65–67% of announced rounds to AI-focused founders. This isn't a recent phenomenon—AI crossed the 60% threshold in late 2025 and has held there. It suggests a structural shift in founder behavior and investor appetite, not a temporary boom.

Where Non-AI Capital Goes

Breaking down the non-AI universe reveals a market still searching for equilibrium after AI monopolized institutional attention.

The largest non-AI sectors by funding volume are less obvious than you might expect:

• Biotech & Health (7.1% of non-AI)—ranging from Flare Therapeutics' $85M Series C to early-stage therapeutic startups and diagnostic platforms
• Climate & Energy (3.9%)—including nuclear, renewable hydrogen, and battery technologies (EnergyX's $225M strategic investment from Eni being a standout)
• Space & Aerospace (2.8%)—satellite, launch, and orbital infrastructure plays
• Fintech & Crypto (2.5%)—smaller rounds than in 2024, signaling investor caution
• Logistics & Supply Chain (1.8%)—including Chinese robotics companies like SENAD's $70M Series C

The remaining 77.7% of non-AI deals fall into a broad "Other" category—beauty tech, dental management, agricultural robotics, quantum computing, real estate fintech, marketplace platforms, and hundreds of vertical solutions. This heterogeneity is, paradoxically, a sign of market health: capital is not fleeing to a single alternative narrative, but rather continuing to flow into the unglamorous infrastructure and vertical SaaS that built the 2010s venture boom.

The Quality Question: Are Non-AI Rounds Smaller?

One hypothesis you might test: if AI captures two-thirds of announcements, does it also capture a higher percentage of capital deployed? The answer requires looking at disclosed round sizes.

Among AI rounds, the median announced size is $18M, with mega-rounds ($100M+) appearing roughly once per day. Among non-AI rounds, the median is notably lower—roughly $8M—but with occasional outliers like $225M strategic investments and $97M growth rounds. The distribution is more bimodal: either small seed/Series A activity, or large late-stage checks from strategic players.

What's particularly telling is the type of capital chasing each bucket. AI funding is almost entirely venture capital—traditional VC firms and new-market operators bidding against each other for allocations. Non-AI funding includes a broader mix: strategic corporate investments (Bayer raising €3B from Apollo; Eni backing EnergyX), growth equity, and crossover rounds from public market players. The presence of strategic capital suggests that large enterprises see venture-backed solutions in non-AI spaces as strategic necessities, not optional innovations.

Geographic Patterns in Non-AI Funding

AI funding skews heavily U.S.-centric, with California and New York accounting for more than half of all announced rounds. Non-AI funding, by contrast, shows more geographic dispersion.

European startups raised a disproportionate share of non-AI capital in June—Austria, Italy, and the UK featuring prominently in cleantech and biotech announcements. India's non-AI venture scene (fintech, agtech, deep tech) raised at a steady pace, largely through regional and family office capital. This suggests that venture investors in non-AI spaces may be more willing to invest geographically than their AI-focused peers, who are largely concentrated in U.S. hubs.

The result: non-AI funding has become the international venture story, while AI funding remains globalized in the sense of ambitions but concentrated in the sense of capital deployment.

The Founder Arbitrage

For founders not building AI products, this environment presents a counter-intuitive advantage. While AI startups face intense competition for capital and valuation compression at the Series A stage (as supply of rounds exceeds supply of "good" opportunities), non-AI startups encounter less frenzied bidding and more rational term sheets.

A Series A round for a climate tech startup or biotech deep-tech company is more likely to be negotiated rather than auctioned. Venture investors have deployed most of their AI commitments and are now rotating capital into the "rest of the economy"—which means founders in those spaces have more leverage and better access to patient capital willing to wait for revenue inflection over two to three years, rather than betting on exponential growth in year one.

This arbitrage won't last. As AI funding eventually consolidates around winners (the majority of AI startups will not raise Series B), venture firms will need to re-deploy dry powder. Non-AI sectors will likely see increased competition by late 2026 or early 2027. The present window—where a biotech round can be funded without three competing offers—is narrow.

What Non-AI Funding Tells Us About 2026

The one-third figure is instructive because it reveals that venture capital, even in the age of AI dominance, has not abandoned its original purpose: funding the next generation of problem-solvers across every industry. The fact that 283 non-AI rounds closed in 30 days—quietly, with less fanfare—suggests that the "AI ate venture capital" narrative is overstated.

What AI has actually done is compress decision-making at the top of the market. Every large VC firm now has an AI strategy. Every limited partner now asks about AI exposure. But this concentration at the mega-round level has created a vacuum at the sub-$20M stage, where non-AI startups are thriving with less competition and more patient capital.

The market, in other words, is bifurcating not by sectors, but by round size and geography. And that bifurcation may be healthier for startup creation than the alternative—where all capital flowed into a single narrative and everyone else starved.

The Sectors to Watch

If you're monitoring venture trends beyond AI, June 2026 suggested three areas of particular momentum:

Biotech with AI-adjacent applications—companies like Flare Therapeutics (raising $85M Series C) and others working in drug discovery, diagnostics, or therapeutics development are seeing strong capital inflows. These startups often use machine learning, but position it as a tool, not the story. Investors are betting on enduring biotech fundamentals, not the latest AI architecture.

Energy transition and resource security—EnergyX's $225M strategic investment from Eni signals that oil and gas majors are now comfortable taking significant venture-scale positions in alternatives. Climate tech raised substantially in June, with emphasis on practical solutions (batteries, hydrogen, grid modernization) rather than speculative technology. This suggests the market has moved past the "let's fund everything green" phase into "let's fund things that actually work."

Orbital and space infrastructure—satellite companies, launch operators, and orbital platforms raised consistently through June. The category is small in terms of deal count but large in terms of capital deployment and strategic importance. Every major aerospace and satellite communications company is now actively acquiring venture-backed capabilities rather than building in-house.

What Happens Next

The trajectory is worth following. If the one-third non-AI figure holds through July and August, it suggests venture capital has found an equilibrium: AI gets the headlines and the mega-checks; everything else gets steady, substantial, but less-celebrated funding. That outcome would be better than either extreme—a venture market that only funds AI, or one where AI funding remains a temporary anomaly.

More likely, the split will widen slightly as mega-AI rounds reach saturation in Series B and beyond, leaving more dry powder for growth-stage non-AI investments. The market self-corrects through capital redeployment, not through regulatory mandate or cultural shift. Venture capital, in other words, is working almost exactly as designed: pursuing returns, which in June 2026 meant betting heavily on AI, but not exclusively.

The 283 non-AI startups that raised in June weren't waiting for AI hype to fade. They were building the future that exists parallel to large language models—in labs, in power plants, in clinics, and in supply chain warehouses. That future is being funded right now, even if nobody's talking about it yet.